Tyrosinemia: Difference between revisions
From WikiMD's Wellness Encyclopedia
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{SI}} | |||
{{Infobox medical condition | |||
| name = Tyrosinemia | |||
| image = [[File:L-tyrosine-skeletal.png|left|thumb|L-Tyrosine]] | |||
| caption = L-Tyrosine, the amino acid involved in tyrosinemia | |||
| field = [[Medical genetics]] | |||
| symptoms = [[Failure to thrive]], [[vomiting]], [[diarrhea]], [[jaundice]], [[hepatomegaly]], [[renal tubular dysfunction]] | |||
| complications = [[Liver failure]], [[renal failure]], [[neurological crises]], [[hepatocellular carcinoma]] | |||
| onset = Infancy or early childhood | |||
| duration = Lifelong | |||
| types = Type I (hepatorenal), Type II (oculocutaneous), Type III (neurological) | |||
| causes = [[Genetic mutation]] in [[FAH]], [[TAT]], or [[HPD]] genes | |||
| risks = [[Consanguinity]], [[family history]] | |||
| diagnosis = [[Blood test]], [[urine test]], [[genetic testing]] | |||
| differential = [[Galactosemia]], [[hereditary fructose intolerance]], [[citrullinemia]] | |||
| treatment = [[Dietary restriction]], [[nitisinone]], [[liver transplantation]] | |||
| medication = [[Nitisinone]] | |||
| prognosis = Variable, depends on type and treatment | |||
| frequency = Rare | |||
}} | |||
{{Short description|A genetic disorder affecting tyrosine metabolism}} | {{Short description|A genetic disorder affecting tyrosine metabolism}} | ||
[[File:Inborn_errors_of_metabolism_of_phenylalanine_and_tyrosine.svg|Diagram showing inborn errors of metabolism related to phenylalanine and tyrosine|thumb|left]] | |||
[[File: | |||
'''Tyrosinemia''' is a genetic disorder characterized by elevated levels of the amino acid [[tyrosine]] in the blood. This condition is caused by a deficiency in one of the enzymes responsible for the breakdown of tyrosine, leading to its accumulation and associated health problems. | '''Tyrosinemia''' is a genetic disorder characterized by elevated levels of the amino acid [[tyrosine]] in the blood. This condition is caused by a deficiency in one of the enzymes responsible for the breakdown of tyrosine, leading to its accumulation and associated health problems. | ||
==Types== | ==Types== | ||
There are three main types of tyrosinemia, each caused by a deficiency in a different enzyme involved in tyrosine metabolism: | There are three main types of tyrosinemia, each caused by a deficiency in a different enzyme involved in tyrosine metabolism: | ||
* '''Tyrosinemia type I''' (hepatorenal tyrosinemia) is the most severe form and is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). This type can lead to liver and kidney failure, as well as neurological problems. | * '''Tyrosinemia type I''' (hepatorenal tyrosinemia) is the most severe form and is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). This type can lead to liver and kidney failure, as well as neurological problems. | ||
* '''Tyrosinemia type II''' (oculocutaneous tyrosinemia) is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT). It primarily affects the eyes, skin, and mental development. | * '''Tyrosinemia type II''' (oculocutaneous tyrosinemia) is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT). It primarily affects the eyes, skin, and mental development. | ||
* '''Tyrosinemia type III''' is the rarest form and is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD). It can lead to neurological problems. | * '''Tyrosinemia type III''' is the rarest form and is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD). It can lead to neurological problems. | ||
==Genetics== | ==Genetics== | ||
[[File:Autorecessive.svg|thumb | [[File:Autorecessive.svg|left|thumb|Tyrosinemia is inherited in an autosomal recessive pattern.]] | ||
Tyrosinemia is inherited in an [[autosomal recessive]] pattern, meaning that an individual must inherit two copies of the defective gene, one from each parent, to be affected by the disorder. Carriers, who have only one copy of the mutated gene, typically do not show symptoms. | Tyrosinemia is inherited in an [[autosomal recessive]] pattern, meaning that an individual must inherit two copies of the defective gene, one from each parent, to be affected by the disorder. Carriers, who have only one copy of the mutated gene, typically do not show symptoms. | ||
==Pathophysiology== | ==Pathophysiology== | ||
[[File:Inborn_errors_of_metabolism_of_phenylalanine_and_tyrosine.svg|thumb | [[File:Inborn_errors_of_metabolism_of_phenylalanine_and_tyrosine.svg|left|thumb|Inborn errors of metabolism of phenylalanine and tyrosine]] | ||
The accumulation of tyrosine and its metabolites in the body can lead to a variety of symptoms and complications, depending on the type of tyrosinemia. In type I, the accumulation of toxic metabolites can cause severe liver and kidney damage. In type II, the buildup of tyrosine affects the eyes and skin, while in type III, neurological issues are more prominent. | The accumulation of tyrosine and its metabolites in the body can lead to a variety of symptoms and complications, depending on the type of tyrosinemia. In type I, the accumulation of toxic metabolites can cause severe liver and kidney damage. In type II, the buildup of tyrosine affects the eyes and skin, while in type III, neurological issues are more prominent. | ||
==Diagnosis== | ==Diagnosis== | ||
Diagnosis of tyrosinemia is typically made through blood and urine tests that measure the levels of tyrosine and its metabolites. Genetic testing can confirm the specific enzyme deficiency and type of tyrosinemia. | Diagnosis of tyrosinemia is typically made through blood and urine tests that measure the levels of tyrosine and its metabolites. Genetic testing can confirm the specific enzyme deficiency and type of tyrosinemia. | ||
==Treatment== | ==Treatment== | ||
Treatment for tyrosinemia varies depending on the type but often includes dietary restrictions to limit tyrosine intake. For type I, the drug nitisinone (NTBC) is used to block the formation of toxic metabolites. Liver transplantation may be necessary in severe cases. | Treatment for tyrosinemia varies depending on the type but often includes dietary restrictions to limit tyrosine intake. For type I, the drug nitisinone (NTBC) is used to block the formation of toxic metabolites. Liver transplantation may be necessary in severe cases. | ||
==Prognosis== | ==Prognosis== | ||
With early diagnosis and appropriate treatment, individuals with tyrosinemia can lead relatively normal lives. However, untreated tyrosinemia, especially type I, can lead to severe complications and reduced life expectancy. | With early diagnosis and appropriate treatment, individuals with tyrosinemia can lead relatively normal lives. However, untreated tyrosinemia, especially type I, can lead to severe complications and reduced life expectancy. | ||
==See also== | |||
== | |||
* [[Phenylketonuria]] | * [[Phenylketonuria]] | ||
* [[Alkaptonuria]] | * [[Alkaptonuria]] | ||
* [[Maple syrup urine disease]] | * [[Maple syrup urine disease]] | ||
==References== | ==References== | ||
{{Reflist}} | {{Reflist}} | ||
[[Category:Inborn errors of metabolism]] | [[Category:Inborn errors of metabolism]] | ||
[[Category:Autosomal recessive disorders]] | [[Category:Autosomal recessive disorders]] {{stub}} | ||
Latest revision as of 23:12, 6 April 2025
Editor-In-Chief: Prab R Tumpati, MD
Obesity, Sleep & Internal medicine
Founder, WikiMD Wellnesspedia &
W8MD's medical weight loss NYC, sleep center NYC
Philadelphia medical weight loss and Philadelphia sleep clinics
| Tyrosinemia | |
|---|---|
 | |
| Synonyms | N/A |
| Pronounce | N/A |
| Specialty | N/A |
| Symptoms | Failure to thrive, vomiting, diarrhea, jaundice, hepatomegaly, renal tubular dysfunction |
| Complications | Liver failure, renal failure, neurological crises, hepatocellular carcinoma |
| Onset | Infancy or early childhood |
| Duration | Lifelong |
| Types | Type I (hepatorenal), Type II (oculocutaneous), Type III (neurological) |
| Causes | Genetic mutation in FAH, TAT, or HPD genes |
| Risks | Consanguinity, family history |
| Diagnosis | Blood test, urine test, genetic testing |
| Differential diagnosis | Galactosemia, hereditary fructose intolerance, citrullinemia |
| Prevention | N/A |
| Treatment | Dietary restriction, nitisinone, liver transplantation |
| Medication | Nitisinone |
| Prognosis | Variable, depends on type and treatment |
| Frequency | Rare |
| Deaths | N/A |
A genetic disorder affecting tyrosine metabolism
Tyrosinemia is a genetic disorder characterized by elevated levels of the amino acid tyrosine in the blood. This condition is caused by a deficiency in one of the enzymes responsible for the breakdown of tyrosine, leading to its accumulation and associated health problems.
Types[edit]
There are three main types of tyrosinemia, each caused by a deficiency in a different enzyme involved in tyrosine metabolism:
- Tyrosinemia type I (hepatorenal tyrosinemia) is the most severe form and is caused by a deficiency of the enzyme fumarylacetoacetate hydrolase (FAH). This type can lead to liver and kidney failure, as well as neurological problems.
- Tyrosinemia type II (oculocutaneous tyrosinemia) is caused by a deficiency of the enzyme tyrosine aminotransferase (TAT). It primarily affects the eyes, skin, and mental development.
- Tyrosinemia type III is the rarest form and is caused by a deficiency of the enzyme 4-hydroxyphenylpyruvate dioxygenase (HPD). It can lead to neurological problems.
Genetics[edit]
Tyrosinemia is inherited in an autosomal recessive pattern, meaning that an individual must inherit two copies of the defective gene, one from each parent, to be affected by the disorder. Carriers, who have only one copy of the mutated gene, typically do not show symptoms.
Pathophysiology[edit]
The accumulation of tyrosine and its metabolites in the body can lead to a variety of symptoms and complications, depending on the type of tyrosinemia. In type I, the accumulation of toxic metabolites can cause severe liver and kidney damage. In type II, the buildup of tyrosine affects the eyes and skin, while in type III, neurological issues are more prominent.
Diagnosis[edit]
Diagnosis of tyrosinemia is typically made through blood and urine tests that measure the levels of tyrosine and its metabolites. Genetic testing can confirm the specific enzyme deficiency and type of tyrosinemia.
Treatment[edit]
Treatment for tyrosinemia varies depending on the type but often includes dietary restrictions to limit tyrosine intake. For type I, the drug nitisinone (NTBC) is used to block the formation of toxic metabolites. Liver transplantation may be necessary in severe cases.
Prognosis[edit]
With early diagnosis and appropriate treatment, individuals with tyrosinemia can lead relatively normal lives. However, untreated tyrosinemia, especially type I, can lead to severe complications and reduced life expectancy.
See also[edit]
References[edit]
<references group="" responsive="1"></references>
